Last updated: 23 July 2019 at 7:58am EST

David Warren Carter Net Worth




The estimated Net Worth of David Warren Carter is at least $2.04 Millón dollars as of 2 November 2009. David Carter owns over 40,000 units of Immunogen stock worth over $1,405,800 and over the last 21 years David sold IMGN stock worth over $629,950.

David Carter IMGN stock SEC Form 4 insiders trading

David has made over 5 trades of the Immunogen stock since 2007, according to the Form 4 filled with the SEC. Most recently David sold 45,000 units of IMGN stock worth $359,550 on 1 November 2010.

The largest trade David's ever made was exercising 50,000 units of Immunogen stock on 17 June 2008 worth over $69,000. On average, David trades about 8,095 units every 62 days since 2003. As of 2 November 2009 David still owns at least 45,000 units of Immunogen stock.

You can see the complete history of David Carter stock trades at the bottom of the page.



What's David Carter's mailing address?

David's mailing address filed with the SEC is , , , , .

Insiders trading at Immunogen

Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... y Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.



What does Immunogen do?

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.



Complete history of David Carter stock trades at Immunogen

Persona
Trans.
Transacción
Precio total
David Warren Carter
Director
Venta $359,550
1 Nov 2010
David Warren Carter
Director
Venta $270,400
2 Nov 2009
David Warren Carter
Director
Uso de opción $69,000
17 Jun 2008
David Warren Carter
Director
Uso de opción $21,000
29 Oct 2007
David Warren Carter
Director
Uso de opción $16,300
12 Apr 2007


Immunogen executives and stock owners

Immunogen executives and other stock owners filed with the SEC include: